AMPLITUDE
77 evidence topics · 27 sources
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Main objective in the EU Clinical Trials Information System record
Scope and secondary objectives of Part A and Part B in the EU register record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2022-03-30” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-06-02” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2030-05-07” (opens the source at this quote in a new tab)
“First Posted 2022-04-06” (opens the source at this quote in a new tab)
“Last Update Posted 2026-10-26” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
EU member states, trial start, and estimated end of trial in the EU Clinical Trials Information System record
“Locations Belgium, France” (opens the source at this quote in a new tab)
“Start of trial 25/10/2022” (opens the source at this quote in a new tab)
“Estimated end of trial date in EU/EEA: 31/05/2028” (opens the source at this quote in a new tab)
“Estimated global end date of the trial: 31/05/2028” (opens the source at this quote in a new tab)
Recruitment end in the EU member states
First authorization and status by country in the earlier EU Clinical Trials Register record
Number of open sites stated by the company in 2023 and 2024
Countries in the phase 3 portion stated in the design abstract
Study design
Design details in the ClinicalTrials.gov record
“Primary Purpose : Treatment” (opens the source at this quote in a new tab)
“Allocation : Randomized” (opens the source at this quote in a new tab)
“Interventional Model : Sequential Assignment” (opens the source at this quote in a new tab)
“Masking : Quadruple” (opens the source at this quote in a new tab)
Integrated phase 2 and phase 3 trial in the EU Clinical Trials Information System record
Single pivotal adaptive trial with a phase 2 dose-selection portion
Phase 2 portion: two doses or placebo for 12 weeks
Dose selection for phase 3 by the independent data monitoring committee
Pediatric cohort: adolescents aged 10 to 17 years added to the phase 3 portion
Pre-planned interim analysis at week 48 in a pre-specified number of participants
Part B open-label extension: 96 additional weeks of inaxaplin
Final analysis triggered by follow-up duration and number of composite outcomes
Independent data monitoring committee in the ClinicalTrials.gov data summarized by the EU register mirror
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
“APOL1 genotype of G1/G1, G2/G2, or G1/G2” (opens the source at this quote in a new tab)
“Proteinuric kidney disease” (opens the source at this quote in a new tab)
“Solid organ or bone marrow transplant” (opens the source at this quote in a new tab)
“Uncontrolled hypertension” (opens the source at this quote in a new tab)
“History of diabetes mellitus” (opens the source at this quote in a new tab)
Ages and sexes eligible in the ClinicalTrials.gov record
Part A inclusion criteria: genotype, age, body size, proteinuria, and kidney function in the EU register record
Part A inclusion criteria: stable background therapy in the EU register record
Part A exclusion criteria in the EU register record
Part B inclusion and exclusion criteria in the EU register record
Eligibility summarized in the 2025 design abstract
Original eligibility at trial start: ages 18 to 60 years
Population described by the company: severe proteinuria and no comorbidities causing kidney disease
Treatment
Arms and interventions in the ClinicalTrials.gov record
Phase 3 dose: inaxaplin 45 mg once daily or placebo added to standard of care
Investigational medicinal product and placebo in the EU register record
| Field | Quoted record |
|---|---|
| Test product | “VX-147 film-coated tablet” |
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |
| Orphan designation number | “EMA/OD/0000090156” |
| Placebo | “VX-147, Coated Placebo Tablet” |
Phase 2 portion: two inaxaplin doses or placebo for 12 weeks
Study outcomes
Rationale for using percent change in UPCR at week 48 and eGFR slope as the primary endpoints
Registered primary outcome measures in the ClinicalTrials.gov record
Registered secondary outcome measures in the ClinicalTrials.gov record
Primary and secondary end points in the EU register record
Final analysis: eGFR slope primary endpoint and composite clinical outcome secondary endpoint
Interim analysis endpoints as first described: eGFR slope supported by proteinuria
Interim analysis endpoints in the design abstract: UPCR and eGFR slope
Discussions with the FDA on the accelerated approval pathway
Interim analysis as the basis for an accelerated approval application
GFR slope as a surrogate endpoint: individual participant data meta-analysis of 66 studies
“Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median R2=0.97 [95% Bayesian credible interval [BCI] 0.82 to 1.00]), and moderately associated with those on chronic slope (R2=0.55 [95% BCI 0.25 to 0.77]). There was no evidence of heterogeneity across disease. Our results support use of total slope as a primary endpoint for clinical trials of CKD progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The slope of the meta-regression line is −0.35 (95% BCI −0.42 to −0.29) per mL/min per 1.73 m2/year), indicating that a 0.75 ml/min per 1.73 m2/year greater beneficial effect of the treatment on the total GFR slope is associated with an average 23.3% lower hazard ratio for the clinical end point (95% BCI 19.3% to 27.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria and GFR slope as end points: NKF workshop with the FDA and EMA
“The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently willing to consider a 30% to 40% glomerular filtration rate (GFR) decline as a surrogate end point for kidney failure for clinical trials of kidney disease progression under appropriate conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that both early change in albuminuria and GFR slope fulfill criteria for surrogacy for use as end points in clinical trials for chronic kidney disease progression under certain conditions, with stronger support for change in GFR than albuminuria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GFR slope qualified by the EMA as a validated surrogate endpoint when clinical endpoints are not feasible
Proteinuria reduction as a reasonably likely surrogate end point for accelerated approval: Kidney Health Initiative
“In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proteinuria as an endpoint in focal segmental glomerulosclerosis: Kidney Health Initiative
“Available data support the use of complete remission of proteinuria in patients with heavy proteinuria as a surrogate endpoint for progression to kidney failure. While substantial treatment effects on proteinuria that are short of a complete remission may also predict the effect of a treatment on progression to kidney failure, further work is needed to determine how such an endpoint should be defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proteinuria reduction and kidney survival in steroid-resistant focal segmental glomerulosclerosis
“A 1 unit reduction in log-transformed urinary protein:creatinine ratio was associated with a 3.90 ml/year rise in eGFR (95% CI=2.01 to 5.79).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was an analogous relationship between time-varying proteinuria and time to end-stage kidney disease: the HR for ESKD or death per 1 unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI=0.12 to 0.44).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change as a surrogate endpoint across 48 randomized trials
“Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change as a surrogate endpoint in APOL1-mediated kidney disease: real-world cohort preprint
“However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory precedent in focal segmental glomerulosclerosis: FDA approval to reduce proteinuria
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the phase 2 and phase 3 portions
Actual enrollment in the ClinicalTrials.gov record
Interim analysis cohort: a pre-specified number of participants at week 48
Number of composite clinical outcomes required for the final analysis
Description of analysis sets
Interim analysis after the interim analysis cohort reaches 48 weeks of treatment
Interim analysis cohort limited to participants with primary AMKD
Duration of eGFR data at the interim and final analyses
Final analysis timing in the design abstract
Results
Participant disposition
APOL1 genotyping study used to identify candidates: interim analysis
Completion of enrollment in the phase 2 dose-ranging portion
Completion of enrollment in the interim analysis cohort in September 2025
Completion of full enrollment in 2026
Enrollment and recruitment status in the ClinicalTrials.gov record
Baseline characteristics
Phase 2 portion: APOL1 genotype, age, and eGFR of 64 dosed participants
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: study limitations
As of November 2026, no efficacy or safety results of AMPLITUDE have been published or posted: the registry record shows 522 participants enrolled, and the company states that data from the week 48 interim analysis are expected in early 2027. The only participant-level data reported are the APOL1 genotype distribution, mean age (42.7 years), and mean eGFR (42.8 mL/min/1.73 m2) of the 64 participants dosed as of the 2025 abstract; the dose-selection results of that portion and its safety data have not been reported. The accelerated approval pathway rests on the week 48 interim analysis of percent change in UPCR and eGFR slope, two surrogate endpoints; the final analysis of eGFR slope requires at least 2 years of eGFR data, and the composite clinical outcome (sustained eGFR decline of at least 30%, end-stage kidney disease, or death) is a secondary endpoint. The supporting surrogate-endpoint evidence comes mainly from other kidney diseases: the EMA notes that for rare diseases “support of efficacy may need to be provided by additional endpoints”, a 2025 review states for proteinuria short of complete remission in FSGS that “further work is needed to determine how such an endpoint should be defined”, and the only analysis specific to APOL1-mediated kidney disease is a real-world analysis of 128 participants. Eligibility required UPCR of 0.7 to less than 10 g/g and eGFR of 25 to less than 75 mL/min/1.73 m2 and excluded people with diabetes, transplantation, uncontrolled hypertension, or another known cause of kidney disease, so the results will not describe people with modest proteinuria or type 2 diabetes, whom the company describes as “populations not being studied in the AMPLITUDE trial”. The registered age range differs between records: the ClinicalTrials.gov record lists 10 to 65 years, and the EU register inclusion criteria list 12 to 65 years for phase 3. The registry lists 314 locations in 13 countries and territories, including the United States. In Part B, participants who complete Part A receive inaxaplin for an additional 96 weeks without a placebo group, and the definitions of the analysis populations have not been published.